In this issue:
Cytogenetic abnormalities impact depths of immunoparesis and survival
GEM-PETHEMA score identifies ND patients at risk for early severe infection
Prolonged PFS with D-Rd vs Rd, regardless of frailty status
Idiotype vaccination plus adoptive autologous T-cell transfer strategy feasible
Front-line dual-antigen targeting CAR T cell therapy consolidation for high-risk disease
Salvage concurrent radiotherapy plus DCEP chemotherapy effective and safe for RRMM
Elotuzumab plus pomalidomide, carfilzomib and dexamethasone for high-risk MM
XKd regimen demonstrates early efficacy in carfilzomib non-refractory RRMM
Outpatient ASCT in MM is feasible and safe
cfDNA for the detection of emerging treatment failure in RRMM
Please login below to download this issue (PDF)